HK1259616A1 - 用於治疗急性肾衰竭的安贝生坦 - Google Patents
用於治疗急性肾衰竭的安贝生坦Info
- Publication number
- HK1259616A1 HK1259616A1 HK19101803.4A HK19101803A HK1259616A1 HK 1259616 A1 HK1259616 A1 HK 1259616A1 HK 19101803 A HK19101803 A HK 19101803A HK 1259616 A1 HK1259616 A1 HK 1259616A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ambesentan
- subject
- administered
- liquid composition
- kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310221P | 2016-03-18 | 2016-03-18 | |
| US62/310,221 | 2016-03-18 | ||
| EP16166046.9A EP3235496A1 (en) | 2016-04-19 | 2016-04-19 | Treatment of acute renal failure |
| EP16166046.9 | 2016-04-19 | ||
| US201662437949P | 2016-12-22 | 2016-12-22 | |
| US62/437,949 | 2016-12-22 | ||
| PCT/EP2017/056476 WO2017158199A1 (en) | 2016-03-18 | 2017-03-20 | Ambrisentan for use in the treatment of acute renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1259616A1 true HK1259616A1 (zh) | 2019-12-06 |
Family
ID=55808404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19101803.4A HK1259616A1 (zh) | 2016-03-18 | 2017-03-20 | 用於治疗急性肾衰竭的安贝生坦 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10870021B2 (https=) |
| EP (3) | EP3235496A1 (https=) |
| JP (1) | JP7237362B2 (https=) |
| KR (1) | KR20180121539A (https=) |
| CN (1) | CN109069443A (https=) |
| AU (1) | AU2017235618B2 (https=) |
| BR (1) | BR112018067602A2 (https=) |
| CA (1) | CA3015432A1 (https=) |
| CL (1) | CL2018002638A1 (https=) |
| DK (1) | DK3429566T3 (https=) |
| ES (2) | ES2966638T3 (https=) |
| HK (1) | HK1259616A1 (https=) |
| IL (1) | IL261457B (https=) |
| MX (1) | MX374534B (https=) |
| SG (1) | SG11201808009SA (https=) |
| WO (1) | WO2017158199A1 (https=) |
| ZA (1) | ZA201805562B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639827A1 (en) * | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| WO2021219691A1 (en) * | 2020-04-29 | 2021-11-04 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| CA2695259C (en) * | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| MX2014010209A (es) | 2012-02-29 | 2014-11-21 | Toray Industries | Agente inhibidor para acumulacion de fluido de la cavidad corporal. |
| CN105324395A (zh) * | 2013-03-08 | 2016-02-10 | 艾伯维公司 | 治疗急性肾损伤的方法 |
| EP2988770A4 (en) | 2013-04-26 | 2016-12-14 | La Jolla Pharma Co | COMPOSITIONS AND METHOD FOR TREATING KIDNEY FAILURES |
| WO2015069839A1 (en) * | 2013-11-06 | 2015-05-14 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
-
2016
- 2016-04-19 EP EP16166046.9A patent/EP3235496A1/en not_active Withdrawn
-
2017
- 2017-03-20 EP EP17711211.7A patent/EP3429566B1/en active Active
- 2017-03-20 MX MX2018011222A patent/MX374534B/es active IP Right Grant
- 2017-03-20 WO PCT/EP2017/056476 patent/WO2017158199A1/en not_active Ceased
- 2017-03-20 BR BR112018067602A patent/BR112018067602A2/pt not_active Application Discontinuation
- 2017-03-20 ES ES20175547T patent/ES2966638T3/es active Active
- 2017-03-20 ES ES17711211T patent/ES2856960T3/es active Active
- 2017-03-20 AU AU2017235618A patent/AU2017235618B2/en active Active
- 2017-03-20 SG SG11201808009SA patent/SG11201808009SA/en unknown
- 2017-03-20 KR KR1020187026495A patent/KR20180121539A/ko not_active Ceased
- 2017-03-20 CN CN201780017563.3A patent/CN109069443A/zh active Pending
- 2017-03-20 CA CA3015432A patent/CA3015432A1/en active Pending
- 2017-03-20 US US16/084,340 patent/US10870021B2/en active Active
- 2017-03-20 JP JP2019500021A patent/JP7237362B2/ja active Active
- 2017-03-20 DK DK17711211.7T patent/DK3429566T3/da active
- 2017-03-20 EP EP20175547.7A patent/EP3878439B1/en active Active
- 2017-03-20 HK HK19101803.4A patent/HK1259616A1/zh unknown
-
2018
- 2018-08-21 ZA ZA2018/05562A patent/ZA201805562B/en unknown
- 2018-08-29 IL IL261457A patent/IL261457B/en unknown
- 2018-09-14 CL CL2018002638A patent/CL2018002638A1/es unknown
-
2020
- 2020-10-07 US US17/065,097 patent/US11642307B2/en active Active
-
2023
- 2023-03-31 US US18/129,516 patent/US20230233454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3429566T3 (da) | 2021-03-29 |
| EP3878439A1 (en) | 2021-09-15 |
| EP3878439B1 (en) | 2023-10-04 |
| ES2966638T3 (es) | 2024-04-23 |
| EP3235496A1 (en) | 2017-10-25 |
| IL261457B (en) | 2021-09-30 |
| NZ746140A (en) | 2022-03-25 |
| ZA201805562B (en) | 2019-06-26 |
| EP3429566A1 (en) | 2019-01-23 |
| EP3429566B1 (en) | 2021-01-27 |
| SG11201808009SA (en) | 2018-10-30 |
| US11642307B2 (en) | 2023-05-09 |
| AU2017235618B2 (en) | 2021-02-25 |
| JP7237362B2 (ja) | 2023-03-13 |
| CA3015432A1 (en) | 2017-09-21 |
| MX374534B (es) | 2025-03-06 |
| IL261457A (en) | 2018-10-31 |
| KR20180121539A (ko) | 2018-11-07 |
| JP2019515942A (ja) | 2019-06-13 |
| WO2017158199A1 (en) | 2017-09-21 |
| US20210046332A1 (en) | 2021-02-18 |
| MX2018011222A (es) | 2019-01-10 |
| ES2856960T3 (es) | 2021-09-28 |
| BR112018067602A2 (pt) | 2019-01-08 |
| US10870021B2 (en) | 2020-12-22 |
| CN109069443A (zh) | 2018-12-21 |
| CL2018002638A1 (es) | 2019-01-18 |
| AU2017235618A1 (en) | 2018-09-27 |
| US20230233454A1 (en) | 2023-07-27 |
| US20190083820A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jo et al. | Pharmacologic treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon | |
| JP3232085B2 (ja) | ラノラジンおよび関連ピペラジン誘導体を使用する新規な処置方法 | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| US20230233454A1 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| JP2021178846A (ja) | ベンダムスチンの製剤 | |
| US20090018136A1 (en) | Methods and compositions for the treatment of vascular disease | |
| JP2016532723A (ja) | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 | |
| JP2021519764A (ja) | 線維性疾患を処置する方法 | |
| US20210361600A1 (en) | Methods for inducing chondrogenesis | |
| NZ746140B2 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| NZ786075A (en) | Ambrisentan for use in the treatment of acute renal failure | |
| JP2022518143A (ja) | ビタミンｅならびにがん治療用組成物および方法 | |
| EP3870176A2 (en) | Use of ambrisentan for the treatment of portal hypertension and cirrhosis | |
| US9682071B2 (en) | Methods of improving microvascular integrity | |
| WO2017202227A1 (zh) | Z-亚丁基苯酞于活化自体免疫系统的应用 | |
| WO2026019771A1 (en) | Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment | |
| Bland-van den Berg | Investigations into the hemodynamic and metabolic effects of fructose 1, 6 diphosphate and prostacyclin in hypovolemic shock |